This Could Be a New Billion-Dollar Market for Moderna

1 min read

In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss Moderna‘s (NASDAQ: MRNA) coronavirus vaccine trial in kids — and what that population may mean for revenue.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Should Investors Worry About This Announcement From Moderna?

Next Story

11 Words From President Biden That Frighten Big Pharma

Latest from Blog